<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384513</url>
  </required_header>
  <id_info>
    <org_study_id>11D.247</org_study_id>
    <secondary_id>2011-31</secondary_id>
    <nct_id>NCT01384513</nct_id>
  </id_info>
  <brief_title>A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies</brief_title>
  <official_title>A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare the survival rates of patients with better&#xD;
      risk disease undergoing hematopoietic stem cell transplant (HSCT) to the survival rates&#xD;
      reported in the medical literature of similar patients undergoing reduced intensity HSCT from&#xD;
      matched related donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the overall survival (OS) rate at 2 years post treatment using the Jefferson 2&#xD;
      step reduced intensity conditioning (RIC) approach in patients with haploidentical family&#xD;
      donors with hematological malignancies in morphological or radiographic remission or with&#xD;
      chemosensitive, indolent diseases to historical OS rates in similar populations after RIC&#xD;
      matched donor HSCT as reported in the literature.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the treatment-related mortality (TRM) rate at 2 years for patients treated on&#xD;
      this study to the historical TRM rates of patients undergoing RIC matched-sibling HSCT as&#xD;
      reported in the literature.&#xD;
&#xD;
      II. To compare the 2 year relapse rates and relapse related mortality of patients with&#xD;
      myeloid diseases to that of patients with lymphoid diseases who are treated on this Thomas&#xD;
      Jefferson University (TJU) RIC 2 step approach.&#xD;
&#xD;
      III. To determine the incidence and severity of graft-versus-host disease (GVHD) in patients&#xD;
      undergoing treated on the TJU RIC 2 step approach.&#xD;
&#xD;
      IV. To evaluate engraftment rates and lymphoid reconstitution in patients treated on the TJU&#xD;
      RIC 2 step approach.&#xD;
&#xD;
      V. To evaluate the incidence of TRM at 100 days in patients treated on the TJU RIC 2 step&#xD;
      approach.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate intravenously (IV)&#xD;
      over 60 minutes on days -11 to -8 and bulsufan IV over 3 hours on days -10 to -9. Patients&#xD;
      undergo total body irradiation (TBI) on day -6. Patients also receive cyclophosphamide IV&#xD;
      over 2 hours on days -3 and -2.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo donor lymphocyte infusion (DLI) on day -6 and cluster of&#xD;
      differentiation (CD)-34+ allogeneic peripheral blood stem cell transplantation (PBSCT) on day&#xD;
      0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or orally (PO) with&#xD;
      taper beginning on day 42. Patients also receive mycophenolate mofetil IV twice daily (BID)&#xD;
      on days -1 to 28.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 4, 2011</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">November 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemosensitive, indolent diseases</measure>
    <time_frame>At 2 years</time_frame>
    <description>The primary null hypothesis is that 2 year OS rate is at most 35%. This hypothesis will be rejected if the 95% confidence interval for year OS rate computed from the estimated Kaplan-Meier survival curves will be entirely above 0.35.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Mortality (TRM)</measure>
    <time_frame>At 2 years</time_frame>
    <description>To compare the treatment related mortality rate (TRM) for patients treated on this study to the historical TRM rates of patients undergoing reduced intensity conditioning (RIC) matched-sibling hematopoietic stem cell transplant (HSCT) as reported in the literature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of GVHD, graded according to standard criteria</measure>
    <time_frame>Assessed up to 2 years</time_frame>
    <description>The estimates of incidence rates will be presented with corresponding 95% confidence intervals using the exact method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>At 2 years</time_frame>
    <description>Evaluated by estimating Kaplan-Meier survival curves. From these curves, the 95% confidence interval for 2 year rates will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment Rates</measure>
    <time_frame>Assessed up to 2 years</time_frame>
    <description>The estimates of incidence rates will be presented with corresponding 95% confidence intervals using the exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Related Mortality (TRM)</measure>
    <time_frame>At 100 days</time_frame>
    <description>The estimates of incidence rates will be presented with corresponding 95% confidence intervals using the exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Related Mortality</measure>
    <time_frame>At 2 years</time_frame>
    <description>Evaluated by estimating Kaplan-Meier survival curves. From these curves, the 95% confidence interval for 2 year rates will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoid Reconstitution</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>To evaluate lymphoid reconstitution in patients treated on the Two Step approach</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Eosinophilic Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chronic Neutrophilic Leukemia</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Mastocytosis</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Myelofibrosis</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Anemia</condition>
  <condition>Refractory Anemia With Ringed Sideroblasts</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>T-cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.&#xD;
TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.&#xD;
GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>Myleran</other_name>
    <other_name>Busulfex IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation (TBI)</intervention_name>
    <description>2 Gy administered as part of the conditioning regimen</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor Lymphocyte Infusion (DLI)</intervention_name>
    <description>Undergo DLI</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>buffy coat fusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CY)</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>Fujimycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo CD34+ allogeneic PBSCT</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>CliniMACS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood stem cell transplantation (PBSCT)</intervention_name>
    <description>Undergo CD34+ allogeneic PBSCT</description>
    <arm_group_label>Treatment (Allogeneic PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation</other_name>
    <other_name>peripheral blood stem cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any patient with hematologic or oncologic diagnosis in which allogeneic HSCT is&#xD;
             thought to be beneficial, and in whom front-line therapy has already been applied.&#xD;
             Patients treated on this protocol will be without morphological evidence of disease&#xD;
             (complete remission or &quot;CR&quot;), or if the patient has evidence of disease, the patient&#xD;
             must have had at least a good partial response (PR) to the most recent therapy and the&#xD;
             disease must be chemoresponsive.&#xD;
&#xD;
          2. Patients treated on this study will have:&#xD;
&#xD;
               -  Acute leukemia in 1st or 2nd CR&#xD;
&#xD;
               -  MDS (myelodysplastic syndrome), specific subtypes of RA (refractory anemia) or&#xD;
                  RARS (refractory anemia with ringed sideroblasts) subtypes.&#xD;
&#xD;
               -  Hodgkin or Indolent Non-Hodgkin's lymphoma with chemosensitive disease&#xD;
&#xD;
               -  Myeloma without morphological evidence of disease, or a deep PR to the most&#xD;
                  recent therapy&#xD;
&#xD;
               -  Myeloproliferative disorders with at least a PR to current therapy&#xD;
&#xD;
               -  Aplastic Anemia&#xD;
&#xD;
               -  A hematological or oncological disease (not listed) that meets the criteria&#xD;
                  reviewed above (in CR or with a good PR).&#xD;
&#xD;
          3. Patients must have a related donor who is HLA mismatched at 2, 3, or 4 antigens at the&#xD;
             HLA-A; B; C; DR loci in the GVHD direction. (Patients with related donors who are HLA&#xD;
             identical or are a 1-antigen mismatch may be treated on this therapeutic approach, but&#xD;
             will have their outcomes will not be part of the statistical aims of the study (see&#xD;
             Summary section).&#xD;
&#xD;
          4. Patients must adequate organ function:&#xD;
&#xD;
               -  LVEF (Left ventricular end diastolic function) of &gt;50%&#xD;
&#xD;
               -  DLCO (Diffusing Capacity of the Lung for Carbon Monoxide ) ≥50% of predicted&#xD;
                  corrected for hemoglobin&#xD;
&#xD;
               -  Adequate liver function as defined by a serum bilirubin &lt;1.8, AST or ALT &lt; 2.5X&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  Creatinine Clearance of ≥ 60 mL/min&#xD;
&#xD;
          5. Performance status ≥ 80% (TJU Karnofsky) for patients ≥ 60 years old or ≥70% for&#xD;
             patients &lt; 60 years old.&#xD;
&#xD;
          6. HCT-CI Score ≤ 4 points for patients ≥ 60 years old or ≤ 5 points for patients &lt; 60&#xD;
             years old.&#xD;
&#xD;
          7. Patients must be willing to use contraception if they have childbearing potential&#xD;
&#xD;
          8. Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Performance status &lt; 80% (TJU Karnofsky) for patients ≥ 60 years old or &lt;70% for&#xD;
             patients &lt; 60.&#xD;
&#xD;
          2. Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score &gt; 4 points for patients&#xD;
             ≥ 60 years old or &gt; 5 points for patients &lt; 60.&#xD;
&#xD;
          3. HIV positive&#xD;
&#xD;
          4. Active involvement of the central nervous system with malignancy&#xD;
&#xD;
          5. Inability to obtain informed consent&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Patients with life expectancy of &lt; 6 months for reasons other than their underlying&#xD;
             hematologic/oncologic disorder&#xD;
&#xD;
          8. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or&#xD;
             who have recently received horse or rabbit anti-thymocyte globulin and have an&#xD;
             anti-thymocyte globulin level of &gt; 2 ugm/ml&#xD;
&#xD;
          9. Patients with evidence of another malignancy, exclusive of a skin cancer that requires&#xD;
             only local treatment, should not be enrolled on this protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Grosso, DNP, CRNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic HSCT</keyword>
  <keyword>Hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Leukemia, Neutrophilic, Chronic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

